To the Editor,

I read with great interest the article by Sun et al. \[[@B1]\]. Pentoxifylline may exert a number of renoprotective effects, besides its role in attenuating diabetic nephropathy. Pentoxifylline attenuates kidney damage secondary to hepatic ischemia/reperfusion injury. It mediates this action by decreasing malondialdehyde levels \[[@B2]\]. Simultaneously, it restores intracellular glutathione. As a result, oxidative injury to the kidneys is mitigated. Obviously, conditions such as hepato-renal syndrome can be avoided with pentoxifylline pretreatment. The coming years may very well see increased use of pentoxifylline as a prophylactic agent to prevent hepatorenal syndrome in patients with concurrent cirrhosis and ascites.

Pentoxifylline is also beneficial in chronic renal disease. It benefits the kidneys by stabilizing renal function and the glomerular filtration rate. Concurrent decreases in inflammatory markers such as tissue necrosis factor-α and high-sensitivity C-reactive protein reflect the attenuation of inflammatory damage in the kidneys. The interleukin-6 level also decreases at the same time \[[@B3]\]. In addition, pentoxifylline helps reduce proteinuria in chronic kidney disease (CKD) patients. Renke et al. \[[@B3]\] recently reported a 26% decline in proteinuria following pentoxifylline therapy in comparison with placebo therapy. Pentoxifylline also decreases proteinuria in CKD patients following renal transplantation. Moreover, pentoxifylline modulates hepcidin function and augments iron release, thereby improving hemoglobin levels in CKD patients.

By virtue of its antioxidant properties, pentoxifylline also mitigates and reduces renal damage secondary to exposure to cigarette smoke. Similarly, pentoxifylline is of benefit in cardiac surgery because it prevents and attenuates acute renal injury \[[@B4]\]. When used in conjunction with albumin, pentoxifylline protects the kidneys from injury following endotoxemic shock, by decreasing inducible nitric oxide synthase expression in the kidneys \[[@B5]\]. Similarly, the postlaparoscopy administration of pentoxifylline attenuates renal ischemia associated with laparoscopy.

These examples clearly illustrate the renoprotective effects of pentoxifylline.
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We thank Dr. Kapoor for the precise comments on the effect of pentoxifylline (PTX) in diabetic nephropathy \[[@BC1]\] and other diseases.

Currently, PTX is used to treat peripheral vascular and bronchoconstrictive diseases \[[@BC2],[@BC3]\]. Recently, the effects of PTX have been determined under various conditions, including antiphospholipid syndrome, alcoholic hepatitis, and wound healing. Several clinical trials of PTX in nonalcoholic steatohepatiti), contrast-induced nephropathy, radiation injury, and other conditions have been conducted.

Unfortunately, the effects of PTX in patients with diabetic nephropathy are unclear. This might be due to the heterogeneous clinical nature of diabetic nephropathy. Of diabetics with chronic kidney disease, 24% to 51% do not have albuminuria \[[@BC4],[@BC5]\]. The resistance of the intrarenal arteries was increased in type 2 diabetics with impaired renal function regardless of proteinuria \[[@BC6]\]. These findings suggest that vasculopathy is a very important risk factor for the progression of diabetic nephropathy. Therefore, the effect of PTX in diabetic patients could differ according to the vascular changes.
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